Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

BioDlink’s Biosimilar Bevacizumab Approved in Indonesia, Pakistan and Columbia

Aug 21, 2025

On 21 August 2025, BioDlink (previously known as TOT BIOPHARM) announced that its Bevacizumab Injection, biosimilar to Roche/Genentech’s Avastin®, has received marketing approval from Indonesia’s National Agency of Drug and Food Control (BPOM).

This news comes just days after BioDlink’s 13 August 2025 announcement that its biosimilar bevacizumab received marketing approval from Pakistan’s Drug Regulatory Authority of Pakistan (DRAP) and Colombia’s National Institute for Surveillance of Medicines and Foods (INVIMA).

BioDlink’s manufacturing facility has received GMP certification in China, Colombia, Brazil, Argentina, Egypt, Indonesia and Pakistan and its global licensee for the bevacizumab biosimilar in emerging markets, Kexing Biopharm, has initiated regulatory filings in 35 countries.